Wall Street Associates’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Wall Street Associates’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-35,200	Closed	-$2.46M	–	213
2016 Q3	$2.46M	Hold	35,200	–	–	0.84%	42
2016 Q2	$1.36M	Hold	35,200	–	–	0.55%	73
2016 Q1	$1.43M	Hold	35,200	–	–	0.59%	72
2015 Q4	$3.12M	Sell	35,200 -84,700	-71%	-$6.69M	0.88%	22
2015 Q3	$8.88M	Sell	119,900 -21,400	-15%	-$1.78M	1.7%	3
2015 Q2	$11.4M	Sell	141,300 -20,800	-13%	-$1.35M	1.08%	15
2015 Q1	$6.79M	Sell	162,100 -37,900	-19%	-$1.08M	0.64%	52
2014 Q4	$3.1M	Hold	200,000	–	–	0.3%	104
2014 Q3	$2.53M	Hold	200,000	–	–	0.26%	114
2014 Q2	$2.87M	Hold	200,000	–	–	0.25%	128
2014 Q1	$2.55M	Buy	+200,000	New	+$2.72M	0.21%	145

Other funds holding EGRX

PAI

ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Wall Street Associates's EGRX Position: Q4 2016 in Review

Wall Street Associates sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2016, closing a stake of 35,200 shares — an estimated $2.46M sold.

Wall Street Associates first reported a position in EGRX in Q1 2014 and held it in 11 quarters. The position peaked at $11.4M in Q2 2015. 149 funds tracked by Wall St. Rank hold EGRX as of Q4 2016.

Wall Street Associates reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
Wall Street Associates sold 35,200 Eagle Pharmaceuticals, Inc. shares in Q4 2016, an estimated $2.46M.
Wall Street Associates first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 11 quarters.
Wall Street Associates's Eagle Pharmaceuticals, Inc. position peaked at $11.4M in Q2 2015.
149 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2016.

Based on Wall Street Associates's 13F filing for Q4 2016, filed 18 Jan 2017.